Premium
Aspirin for recurrence prevention in bipolar disorder—Promising, yet clinically understudied?
Author(s) -
Haarman Bartholomeus CM,
Boer Marrit K,
Gaag Christiaan M,
Burger Huib,
Nolen Willem A,
Schoevers Robert A
Publication year - 2019
Publication title -
bipolar disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.285
H-Index - 129
eISSN - 1399-5618
pISSN - 1398-5647
DOI - 10.1111/bdi.12731
Subject(s) - aspirin , cyclooxygenase , medicine , arachidonic acid , pharmacology , thromboxane , bipolar disorder , prostaglandin , relapse prevention , bioinformatics , platelet , lithium (medication) , enzyme , psychiatry , chemistry , biochemistry , biology
Current available maintenance pharmacotherapy for bipolar disorder (BD) leaves ample room for improvement. Up to 50% of patients with BD do not respond adequately to available treatments and still suffer from manic and/or depressive episodes. Although a number of pharmaceutical companies have invested in novel medications, none of the recently developed compounds has shown efficacy for recurrence prevention. This article is protected by copyright. All rights reserved.